Xbrane Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	93.56	124.33	65.4	193.99	295.18	243.14
Cash & Short-Term Investments	93.56	124.33	65.4	193.99	295.18	243.14
Cash Growth	205.85%	90.10%	-66.29%	-34.28%	21.40%	48.08%
Accounts Receivable	3.9	16.85	-	1.34	-	51.38
Other Receivables	5.47	76.01	71.18	46.12	108.3	23.79
Receivables	9.37	92.87	71.18	47.46	108.3	75.17
Inventory	201.73	246.9	106.86	50.26	-	-
Prepaid Expenses	91.93	8.07	16.89	13	2.31	1.21
Other Current Assets	0.86	133.73	201.37	208.81	155.21	54.96
Total Current Assets	397.45	605.9	461.69	513.52	561.01	374.48
Property, Plant & Equipment	0.09	64.9	88.2	71.05	73.8	14.14
Goodwill	-	-	-	-	-	58.45
Long-Term Deferred Charges	303.94	167.69	99.67	102	49.67	4.08
Other Long-Term Assets	-	3.95	3.95	3.95	3.95	12.61
Total Assets	701.48	842.43	653.51	690.52	688.43	463.76
Accounts Payable	39.67	242.57	30.97	23.3	41.39	29.55
Accrued Expenses	73.36	41.19	140.89	66.48	65.76	41.22
Current Portion of Long-Term Debt	-	82.5	62.5	-	-	-
Current Portion of Leases	-	13.27	13.37	9.16	7.91	2.27
Current Unearned Revenue	-	147.26	75.41	136.06	95.39	115.96
Other Current Liabilities	1.4	11.15	3.42	1.56	9.22	0
Total Current Liabilities	114.43	537.94	326.56	236.57	219.67	188.99
Long-Term Debt	-	66.37	112.9	-	-	-
Long-Term Leases	-	29.58	42.71	29.06	36.48	4
Long-Term Unearned Revenue	-	-	-	-	0.54	8.26
Other Long-Term Liabilities	-0	-0	0.01	-	-	4.81
Total Liabilities	114.43	633.89	482.17	265.63	256.69	206.06
Common Stock	577.43	343.5	6.68	6.17	5.61	4.98
Additional Paid-In Capital	1,386	1,395	1,429	1,294	1,134	773.72
Retained Earnings	-1,386	-1,540	-1,274	-885.83	-713.31	-524.94
Comprehensive Income & Other	10.15	10.23	10.12	10.32	5.16	3.95
Shareholders' Equity	587.05	208.54	171.34	424.89	431.74	257.71
Total Liabilities & Equity	701.48	842.43	653.51	690.52	688.43	463.76
Total Debt	-	191.72	231.48	38.22	44.38	6.26
Net Cash (Debt)	93.56	-67.39	-166.08	155.77	250.8	236.88
Net Cash Growth	-	-	-	-37.89%	5.88%	53.06%
Net Cash Per Share	5.05	-6.85	-723.19	761.51	1328.76	1634.70
Filing Date Shares Outstanding	20.61	12.24	0.24	0.22	0.2	0.18
Total Common Shares Outstanding	20.61	12.24	0.24	0.22	0.2	0.18
Working Capital	283.02	67.96	135.14	276.96	341.34	185.49
Book Value Per Share	28.49	17.04	718.44	1930.89	2155.27	1451.03
Tangible Book Value	587.05	208.54	171.34	424.89	431.74	199.26
Tangible Book Value Per Share	28.49	17.04	718.44	1930.89	2155.27	1121.91
Machinery	-	62.43	61.93	-	43.49	28.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.